Reasons for Treatment Changes in Patients With Moderate to Severe Psoriasis

被引:5
|
作者
Anderson, Kathryn L. [1 ]
Feldman, Steven R. [1 ,2 ,3 ]
机构
[1] Wake Forest Sch Med, Dept Dermatol, Ctr Dermatol Res, Winston Salem, NC 27157 USA
[2] Wake Forest Sch Med, Dept Pathol, Winston Salem, NC 27157 USA
[3] Wake Forest Sch Med, Dept Publ Hlth Sci, Winston Salem, NC 27157 USA
关键词
psoriasis; phototherapy; dermatology; TREATMENT PATTERNS; DRUG SURVIVAL; BIOLOGICS; DISCONTINUATION; POPULATION; ETANERCEPT; ADALIMUMAB; CARE; IMPAIRMENT; THERAPIES;
D O I
10.1177/1203475415572797
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Background: Psoriasis treatment involves multiple treatment arms. Treatment choice depends on many factors and may change, due to the chronicity of psoriasis. Objective: The purpose of our study is to explore reasons for treatment changes in patients with moderate to severe psoriasis. Methods: Ten charts of patients with moderate to severe psoriasis were reviewed. The medication changes and reasons for change were extracted. A treatment change was defined as switching between medication classes, adding or removing a medication class, or switching medications within the oral or biologic medication class. Results: Seventy-seven treatment changes were identified. On average, I treatment change occurred per year of follow-up. The most common reason for treatment change was inadequate disease control. Conclusions: Inadequate disease control with current therapy is the most common reason a physician changes treatment for moderate to severe psoriasis. More efficacious treatments or ways to improve efficacy may help improve the long-term outcomes of psoriasis.
引用
收藏
页码:361 / 366
页数:6
相关论文
共 50 条
  • [21] Economic evaluation of systemic therapies for moderate to severe psoriasis
    Sizto, S.
    Bansback, N.
    Feldman, S. R.
    Willian, M. K.
    Anis, A. H.
    BRITISH JOURNAL OF DERMATOLOGY, 2009, 160 (06) : 1264 - 1272
  • [22] Potential role of ixekizumab in the treatment of moderate-to-severe plaque psoriasis
    Ren, Vicky
    Dao, Harry, Jr.
    CLINICAL COSMETIC AND INVESTIGATIONAL DERMATOLOGY, 2013, 6 : 75 - 80
  • [23] Moderate to severe psoriasis treatment challenges through the era of biological drugs
    Vide, Julia
    Magina, Sofia
    ANAIS BRASILEIROS DE DERMATOLOGIA, 2017, 92 (05) : 667 - 673
  • [24] Clinical Utility of Guselkumab in the Treatment of Moderate-to-Severe Plaque Psoriasis
    Light, Jeremy G.
    Su, Jennifer J.
    Feldman, Steven R.
    CLINICAL COSMETIC AND INVESTIGATIONAL DERMATOLOGY, 2021, 14 : 55 - 63
  • [25] Oral tofacitinib for the treatment of adults with moderate to severe chronic plaque psoriasis
    Korman, Abraham M.
    Hill, Dane
    Alikhan, Ali
    Feldman, Steven R.
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2016, 9 (04) : 525 - 539
  • [26] Ixekizumab for the treatment of moderate-to-severe plaque psoriasis: the first septennium
    Carmona-Rocha, Elena
    Puig, Lluis
    IMMUNOTHERAPY, 2023, 15 (15) : 1209 - 1225
  • [27] Treatment response in patients with moderate-to-severe psoriasis who had inadequate response to prior secukinumab
    Chiu, Tai-Siang
    Tsai, Tsen-Fang
    DERMATOLOGICA SINICA, 2019, 37 (03) : 129 - 133
  • [28] Efficacy of adalimumab in the treatment of moderate-to-severe psoriasis: A retrospective study of 100 patients in daily practice
    Armesto, Susana
    Coto-Segura, Pablo
    Mayorga, Jesus
    Illaro, Aitziber
    Santos-Juanes, Jorge
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2015, 26 (01) : 49 - 53
  • [29] Risankizumab for the treatment of moderate to severe psoriasis
    Chiricozzi, Andrea
    Antonioli, Luca
    Panduri, Salvatore
    Fornai, Matteo
    Romanelli, Marco
    Blandizzi, Corrado
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2019, 19 (01) : 1 - 8
  • [30] Drug focus: adalimumab in the treatment of moderate to severe psoriasis
    Vena, Gino A.
    Cassano, Nicoletta
    BIOLOGICS-TARGETS & THERAPY, 2007, 1 (02) : 93 - 103